Breaking News, Collaborations & Alliances

Artios In-Licenses First Nuclease Drug Development Program

Under its research collaboration and option agreement with Masaryk University in the Czech Republic

Artios Pharma, a leading DNA Damage Response company developing innovative new treatments for cancer, has exercised its option to in-license the first nuclease drug development program under its research collaboration and option agreement with Masaryk University in the Czech Republic. The collaboration was formed in June 2017 to discover and develop novel cancer treatments by targeting DNA nucleases involved in the DDR.   Commenting on today’s announcement, Niall Martin, chief exec...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters